{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T08:02:10Z","timestamp":1791014530612,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,7,4]],"date-time":"2012-07-04T00:00:00Z","timestamp":1341360000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s00280-012-1908-9","type":"journal-article","created":{"date-parts":[[2012,7,3]],"date-time":"2012-07-03T12:39:14Z","timestamp":1341319154000},"page":"321-329","source":"Crossref","is-referenced-by-count":33,"title":["In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase"],"prefix":"10.1007","volume":"70","author":[{"given":"Eric J.","family":"Sorscher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula W.","family":"Allan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Waud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William B.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,7,4]]},"reference":[{"key":"1908_CR1","unstructured":"Takimoto CH, Calvo E (2009) Chapter 3: principles of oncologic pharmacotherapy. In: Cancer management handbook, 11th edn. UBM Medica, London"},{"issue":"1","key":"1908_CR2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.molmed.2009.11.001","volume":"16","author":"L Sang","year":"2010","unstructured":"Sang L, Roberts JM, Coller HA (2010) Hijacking HES1: how tumors co-opt the anti-differentiation strategies of quiescent cells. Trends Mol Med 16(1):17\u201326","journal-title":"Trends Mol Med"},{"issue":"3","key":"1908_CR3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/sj.bjc.6602710","volume":"93","author":"HR Mellor","year":"2005","unstructured":"Mellor HR, Ferguson DJP, Callaghan R (2005) A model of quiescent tumor microregions for evaluating multicellular resistance to chemotherapeutic drugs. Br J Cancer 93(3):302\u2013309","journal-title":"Br J Cancer"},{"issue":"9","key":"1908_CR4","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.4161\/cbt.6.9.4828","volume":"6","author":"RL Vessella","year":"2007","unstructured":"Vessella RL, Pantel K, Mohla S (2007) Tumor cell dormancy: an NCI workshop report. Cancer Biol Ther 6(9):1496\u20131504","journal-title":"Cancer Biol Ther"},{"issue":"24","key":"1908_CR5","doi-asserted-by":"crossref","first-page":"9245","DOI":"10.1158\/0008-5472.CAN-09-2802","volume":"69","author":"AP Kusumbe","year":"2009","unstructured":"Kusumbe AP, Bapat SA (2009) Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res 69(24):9245\u20139253","journal-title":"Cancer Res"},{"issue":"8","key":"1908_CR6","first-page":"881","volume":"37","author":"S Sal","year":"1991","unstructured":"Sal S, Takashi M, Miyake K, Koshikawa T (1991) Study of growth fraction on fine needle aspirated prostatic tissue smear using monoclonal antibody Ki-67. Hinyokika Kiyo 37(8):881\u2013886","journal-title":"Hinyokika Kiyo"},{"key":"1908_CR7","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1002\/1097-0142(19910615)67:12<3065::AID-CNCR2820671222>3.0.CO;2-U","volume":"67","author":"MV Sadi","year":"1991","unstructured":"Sadi MV, Barrack ER (1991) Determination of growth fraction in advanced prostate cancer by Ki-67 immunostaining and its relationship to the time to tumor progression after hormonal therapy. Cancer 67:3065\u20133071","journal-title":"Cancer"},{"key":"1908_CR8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1172\/JCI115026","volume":"87","author":"DLM Tay","year":"1991","unstructured":"Tay DLM, Bhathal PS, Fox RM (1991) Quantitation of G0 and G1 phase cells in primary carcinomas. J Clin Invest 87:519\u2013527","journal-title":"J Clin Invest"},{"issue":"2","key":"1908_CR9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF00692849","volume":"74","author":"F Giangaspero","year":"1987","unstructured":"Giangaspero F, Doglioni C, Rivano MT, Pileri S, Gerdes J, Stein H (1987) Growth fraction in human brain tumors defined by the monoclonal antibody Ki-67. Acta Neuropathol 74(2):179\u2013182","journal-title":"Acta Neuropathol"},{"key":"1908_CR10","unstructured":"DeVita VT, Lawrence TS, Rosenberg SA (2008) Principles and practice of oncology. In: Ronald A. DePinho, Robert A. Weinbert (eds), 8th Edn. Lippincott Williams & Wilkins, Philadelphia"},{"key":"1908_CR11","volume-title":"Principles and Practice of Radiation Therapy","author":"CM Washington","year":"2009","unstructured":"Washington CM, Leaver DT (2009) Principles and Practice of Radiation Therapy, 3rd edn. Mosby, Philadelphia","edition":"3"},{"issue":"12","key":"1908_CR12","first-page":"5203","volume":"29","author":"S Osada","year":"2009","unstructured":"Osada S, Yoshida K, Saji S (2009) A novel strategy by cryoablation for advanced hepatoma. Anticancer Res 29(12):5203\u20135209","journal-title":"Anticancer Res"},{"issue":"8","key":"1908_CR13","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3109\/02656736.2010.485593","volume":"26","author":"S Krishnan","year":"2010","unstructured":"Krishnan S, Diagaradjane P, Cho SH (2010) Nanoparticle-mediated thermal therapy: evolving strategies for prostate cancer therapy. Int J Hyperthermia 26(8):775\u2013789","journal-title":"Int J Hyperthermia"},{"issue":"5","key":"1908_CR14","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1089\/end.2009.0624","volume":"24","author":"M Margreiter","year":"2010","unstructured":"Margreiter M, Marberger M (2010) Focal therapy and imaging in prostate and kidney cancer: high-intensity focused ultrasound ablation of small renal tumors. J Endourol 24(5):745\u2013746","journal-title":"J Endourol"},{"issue":"4","key":"1908_CR15","first-page":"421","volume":"11","author":"GW Both","year":"2009","unstructured":"Both GW (2009) Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment. Curr Opin Mol Ther 11(4):421\u2013432","journal-title":"Curr Opin Mol Ther"},{"issue":"2","key":"1908_CR16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.canlet.2008.04.023","volume":"270","author":"C Altaner","year":"2008","unstructured":"Altaner C (2008) Prodrug gene therapy. Cancer Lett 270(2):191\u2013201","journal-title":"Cancer Lett"},{"issue":"11","key":"1908_CR17","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.3390\/molecules14114517","volume":"14","author":"GU Dachs","year":"2009","unstructured":"Dachs GU, Hunt MA, Syddall S, Singleton DC, Patterson AV (2009) Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules 14(11):4517\u20134545","journal-title":"Molecules"},{"issue":"9","key":"1908_CR18","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/cgt.2010.17","volume":"17","author":"CK Tai","year":"2010","unstructured":"Tai CK, Wang W, Lai YH, Logg CR, Parker WB, Li YF, Hong JS, Sorscher EJ, Chen TC, Kasahara N (2010) Enhanced efficiency of prodrug activation therapy by tumor-selective replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene. Cancer Gene Ther 17(9):614\u2013623","journal-title":"Cancer Gene Ther"},{"key":"1908_CR19","doi-asserted-by":"crossref","unstructured":"Xie X, Guo J, Kong Y, Xie GX, Li L, Lv N, Xiao X, Tang J, Wang X, Liu P, Yang M, Xie Z, Wei W, Xie X (2011) Targeted expression of Escherichia coli purine nucleoside phosphorylase and Fludara\u00ae for prostate cancer therapy. J Gene Med 13:680\u2013691. doi: 10.1002\/jgm.1620","DOI":"10.1002\/jgm.1620"},{"issue":"6","key":"1908_CR20","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/cgt.2011.4","volume":"18","author":"WB Parker","year":"2011","unstructured":"Parker WB, Allan PW, Waud WR, Hong JS, Sorscher EJ (2011) Effect of expression of adenine phosphoribosyltransferase on the in vivo anti-tumor activity of prodrugs activated by E. coli purine nucleoside phosphorylase. Cancer Gene Ther 18(6):390\u2013398","journal-title":"Cancer Gene Ther"},{"issue":"8","key":"1908_CR21","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/cgt.2011.30","volume":"18","author":"S Bossow","year":"2011","unstructured":"Bossow S, Grossardt C, Temme A, Leber MF, Sawall S, Rieber EP, Cattaneo R, von Kalle C, Ungerechts G (2011) Armed and targeted measles virus for chemovirotherapy of pancreatic cancer. Cancer Gene Ther 18(8):598\u2013608","journal-title":"Cancer Gene Ther"},{"key":"1908_CR22","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1158\/0008-5472.CAN-04-0012","volume":"64","author":"JS Hong","year":"2004","unstructured":"Hong JS, Waud WR, Levasseur DN, Townes TM, Wen H, McPherson SA, Moore BA, Bebok Z, Allan PW, Secrist JA 3rd, Parker WB, Sorscher EJ (2004) Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res 64:6610\u20136615","journal-title":"Cancer Res"},{"key":"1908_CR23","doi-asserted-by":"crossref","first-page":"32552","DOI":"10.1074\/jbc.M111.236117","volume":"286","author":"SY Yao","year":"2011","unstructured":"Yao SY, Ng AM, Cass CE, Baldwin SA, Young JD (2011) Nucleobase transport by human equilibrative nucleoside transporter 1 (hENT1). J Biol Chem 286:32552\u201332562","journal-title":"J Biol Chem"},{"key":"1908_CR24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10555-007-9044-4","volume":"26","author":"J Zhang","year":"2007","unstructured":"Zhang J, Visser F, King KM, Baldwin SA, Young JD, Cass CE (2007) The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Rev 26:85\u2013110","journal-title":"Cancer Metastasis Rev"},{"key":"1908_CR25","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0006-2952(98)00034-3","volume":"55","author":"WB Parker","year":"1998","unstructured":"Parker WB, Allan PW, Shaddix SC, Rose LM, Speegle HF, Gillespie GY, Bennett LL Jr (1998) Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem Pharmacol 55:1673\u20131681","journal-title":"Biochem Pharmacol"},{"key":"1908_CR26","first-page":"2075","volume":"3","author":"LJ Lockett","year":"1997","unstructured":"Lockett LJ, Molloy PL, Russell PJ, Both GW (1997) Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors. Clin Cancer Res 3:2075\u20132080","journal-title":"Clin Cancer Res"},{"key":"1908_CR27","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/sj.gt.3300561","volume":"4","author":"U Nestler","year":"1997","unstructured":"Nestler U, Heinkelein M, Lucke M, Meixensberger J, Scheurlen W, Kretschmer A, Rethwilm A (1997) Foamy virus vectors for suicide gene therapy. Gene Ther 4:1270\u20131277","journal-title":"Gene Ther"},{"key":"1908_CR28","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1089\/10430349950018724","volume":"10","author":"M Puhlmann","year":"1999","unstructured":"Puhlmann M, Gnant M, Brown CK, Alexander HR, Bartlett DL (1999) Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. Human Gene Ther 10:649\u2013657","journal-title":"Human Gene Ther"},{"key":"1908_CR29","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1073\/pnas.93.5.1831","volume":"93","author":"M Mesnil","year":"1996","unstructured":"Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H (1996) Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 93:1831\u20131835","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-1908-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-012-1908-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-1908-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T06:11:22Z","timestamp":1559023882000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-012-1908-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,4]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["1908"],"URL":"https:\/\/doi.org\/10.1007\/s00280-012-1908-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,4]]}}}